NICE guidance - orlistat for the treatment of obesity
Summary points of the guidance on the use of orlistat for the treatment of obesity in adults:
- orlistat should be prescribed only as part of an overall plan for managing obesity in adults who meet one of the following criteria:
- a BMI of 28.0 kg/m2 or more with associated risk factors
- a BMI of 30.0 kg/m2 or more
- therapy should be continued beyond 3 months only if the person has lost at least 5% of their initial body weight since starting drug treatment
- the decision to use drug treatment for longer than 12 months (usually for weight maintenance) should be made after discussing potential benefits and limitations with the patient
- the co-prescribing of orlistat with other drugs aimed at weight reduction is not recommended
Notes:
- rates of weight loss may be slower in people with type 2 diabetes, so less strict goals than those for people without diabetes may be appropriate. These goals should be agreed with the person and reviewed regularly
Reference:
- NICE. Obesity: identification, assessment and management. Clinical guideline CG189. Published: 27 November 2014 Last updated: 26 July 2023
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.